Clinical Trial

Magnesium and Riboflavin Treatment for Post-Concussion Headache

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated March 27, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
This clinical trial will try to determine if the supplements magnesium and riboflavin will reduce the pain and duration of headaches in persons diagnosed with a concussion. The participant will be randomized to either active magnesium and riboflavin capsules or placebo (inert) capsules. The capsules will be taken once a day for 14 days. The participant will also complete a short diary form for the 14 days and will have 3 follow up visits either by telephone or in person.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-02-06; most recent amendment 2025-03-24.
Trial Details
NCT Number NCT06260072
Lead Sponsor University of Virginia
Conditions Concussion, Intermediate
Enrollment 108 participants
Start Date 2020-02-10
Primary Completion 2025-12-31 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-03-27